Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

STOK – Stoke Therapeutics, Inc.

Float Short %

24.52

Margin Of Safety %

-29

Put/Call OI Ratio

0.09

EPS Next Q Diff

-0.12

EPS Last/This Y

1.7

EPS This/Next Y

-3.13

Price

30.87

Target Price

32.71

Analyst Recom

1

Performance Q

40.38

Relative Volume

0.51

Beta

1.11

Ticker: STOK




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-10STOK22.360.130.019292
2025-11-11STOK25.120.110.1011321
2025-11-12STOK25.130.110.1311374
2025-11-13STOK26.070.110.0811267
2025-11-14STOK26.530.110.3511295
2025-11-17STOK26.920.122.2711521
2025-11-18STOK28.920.132.9811610
2025-11-19STOK28.480.160.1811907
2025-11-20STOK27.770.160.3511836
2025-11-21STOK29.330.160.0011827
2025-11-24STOK30.310.090.038851
2025-11-25STOK29.810.090.639143
2025-11-26STOK31.180.092.229188
2025-12-01STOK30.10.090.009299
2025-12-02STOK29.780.090.249315
2025-12-03STOK30.910.090.039324
2025-12-04STOK31.070.090.469423
2025-12-05STOK30.860.090.339396
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




18 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-10STOK22.37-350.0- 0.31
2025-11-11STOK25.11-350.0- 0.31
2025-11-12STOK25.15-350.0- 0.31
2025-11-13STOK26.06-350.0- 0.31
2025-11-14STOK26.54-350.0- 0.04
2025-11-17STOK26.92-350.0- 0.04
2025-11-18STOK28.93-295.8- 0.04
2025-11-19STOK28.48-295.8- 0.04
2025-11-20STOK27.88-297.9- 0.04
2025-11-21STOK29.34-297.9- 0.05
2025-11-24STOK30.33-297.9- 0.05
2025-11-25STOK29.82-297.9- 0.05
2025-11-26STOK31.20-297.9- 0.05
2025-12-01STOK30.09-297.9- 0.05
2025-12-02STOK29.81-297.9- 0.05
2025-12-03STOK30.96-297.9- 0.05
2025-12-04STOK31.06-297.9- 0.05
2025-12-05STOK30.87-297.9- 0.05
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
18 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-10STOK-28.66-2.9522.06
2025-11-11STOK-28.67-2.9522.06
2025-11-12STOK-28.67-2.9521.73
2025-11-13STOK-28.67-2.9521.73
2025-11-14STOK-28.67-2.9521.73
2025-11-17STOK-28.674.3221.73
2025-11-18STOK-28.934.3223.29
2025-11-19STOK-22.374.3223.29
2025-11-20STOK-22.374.3223.29
2025-11-21STOK-22.374.3223.29
2025-11-24STOK-22.374.2323.27
2025-11-25STOK-22.444.2323.27
2025-11-26STOK-22.664.2324.54
2025-12-01STOK-22.664.1424.52
2025-12-02STOK-22.724.1424.52
2025-12-03STOK-22.724.1424.52
2025-12-04STOK-22.784.1424.52
2025-12-05STOK-22.744.1424.52
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-0.65

Avg. EPS Est. Current Quarter

-0.72

Avg. EPS Est. Next Quarter

-0.78

Insider Transactions

-22.74

Institutional Transactions

4.14

Beta

1.11

Average Sales Estimate Current Quarter

5

Average Sales Estimate Next Quarter

3

Fair Value

21.88

Quality Score

63

Growth Score

27

Sentiment Score

67

Actual DrawDown %

56.9

Max Drawdown 5-Year %

-95.2

Target Price

32.71

P/E

46.78

Forward P/E

PEG

P/S

8.57

P/B

5.52

P/Free Cash Flow

33.67

EPS

0.66

Average EPS Est. Cur. Y​

0.05

EPS Next Y. (Est.)

-3.08

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

19.73

Relative Volume

0.51

Return on Equity vs Sector %

-13.7

Return on Equity vs Industry %

1.2

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.22

EBIT Estimation

Stoke Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 128
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
stock quote shares STOK – Stoke Therapeutics, Inc. Stock Price stock today
news today STOK – Stoke Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch STOK – Stoke Therapeutics, Inc. yahoo finance google finance
stock history STOK – Stoke Therapeutics, Inc. invest stock market
stock prices STOK premarket after hours
ticker STOK fair value insiders trading